AFLAC Inc. Stock (US0010551028): Q1 2026 Earnings Surge on Investment Gains and Buybacks

AFLAC Inc. has reported a substantial rebound in net earnings for the first quarter of 2026, with net income rising to $1.019 billion from $29 million in the same quarter a year earlier, according to the company's latest quarterly filing. Total revenues increased to $4.346 billion from $3.398 billion, reflecting strong growth in investment income and a swing from prior?year investment losses to gains. Premiums remained stable at $3.310 billion, while net investment income held at $956 million, and the company recorded $49 million of net investment gains versus a $963 million loss in the prior?year quarter.

Benefits and expenses declined to $3.121 million, supporting an increase in earnings per diluted share to $1.98 from $0.05. Pretax earnings rose to $1.225 billion from $145 million, driven mainly by the turnaround in net investment gains. Segment data show balanced contribution: Aflac Japan pretax adjusted earnings were $759 million, Aflac U.S. delivered $363 million, and Corporate and other was roughly breakeven. Operating cash flow was solid at $968 million, which comfortably covered $304 million of dividends and $1.0 billion of share repurchases in the quarter.

As of March 31, 2026, total assets stood at $116.3 billion and shareholders’ equity at $30.0 billion. The company’s strong cash generation enabled a capital return program of $1.304 billion in the quarter, underscoring its focus on returning value to shareholders. The latest results follow a prior?year quarter marked by significant investment losses, which now appear to have been reversed, contributing to the sharp year?over?year improvement in profitability.

The stock traded at $113.69 on the NYSE on May 8, 2026, at 4:00 PM ET, according to Robinhood data, reflecting a market capitalization of approximately $57.5 billion. The price?to?earnings ratio is around 12.9x, with a dividend yield of about 2.1%. Over the past year, the stock has delivered a total return of roughly 9.3%, according to Simply Wall St, while remaining below some intrinsic?value estimates that suggest upside potential relative to the current share price.

Analysts’ consensus rating for AFLAC Inc. is currently “Hold,” with an average price target of about $111.36, according to MarketBeat. The company’s valuation metrics sit above the broader insurance industry average on price?to?earnings but below the peer group average, indicating a mixed but generally reasonable valuation stance. The latest earnings beat expectations on revenue, which rose 27.9% year?over?year to $4.24 billion, while earnings per share of $1.75 slightly missed the $1.80 consensus, according to MarketBeat.

Recent insider activity also reflects ongoing confidence in the company’s trajectory. On May 6, 2026, director Miwako Hosoda sold 243 shares under a pre?arranged Rule 10b5?1 plan at an average price of $114.50, trimming her holding by about 3.04% to 7,743 shares valued at approximately $886,574. Such transactions are typically part of structured trading plans and do not necessarily signal a change in long?term outlook.

For US investors, AFLAC Inc. remains a prominent player in the supplemental insurance space, listed on the New York Stock Exchange and denominated in US dollars. The company’s dual?market presence in the United States and Japan provides geographic diversification, while its focus on cancer, accident, and critical?illness coverage aligns with long?term demographic trends in both markets. The combination of stable premiums, improved investment performance, and disciplined capital return supports a profile that may appeal to income?oriented and value?oriented investors.

However, risks remain, including sensitivity to interest rates, equity market volatility, and regulatory developments in both the United States and Japan. The company’s reliance on investment income means that future performance could be affected by changes in capital markets, while competition from other insurers and alternative financial products may pressure pricing and margins. Additionally, any shift in mortality or morbidity experience, particularly in its core cancer and critical?illness lines, could impact claims and profitability.

Looking ahead, investors will watch for continued execution on capital return, including the pace of share repurchases and dividend policy, as well as trends in investment performance and underlying premium growth. The company’s ability to maintain or expand its operating margins while navigating macroeconomic and regulatory environments will be key to sustaining the recent earnings rebound. Upcoming earnings dates, regulatory filings, and any changes in analyst sentiment or guidance will provide further signals on the stock’s trajectory.

In summary, AFLAC Inc.’s Q1 2026 results highlight a strong recovery in profitability, driven by investment gains and lower benefits and expenses, alongside robust cash generation and significant shareholder returns. The stock trades at a moderate valuation with a modest dividend yield, reflecting a balance between growth and income characteristics. For US investors seeking exposure to a diversified supplemental insurer with a history of capital discipline, the company’s latest performance offers a concrete data point to assess its current positioning.